What is the cost of illness of type II Diabetes Mellitus in a Developing Economy?

International Journal of Pharmacy and Pharmaceutical Sciences

Volumn 6, Issue SUPPL. 2, 2014, Pages 927-931

  Abdulganiyu, Giwa ^a   Fola, Tayo ^b  

^a UNIVERSITY OF ILORIN   (Nigeria)

^b West African College of Physicians   (Nigeria)

Author keywords

Cost of Illness Analysis; Developing Economy; Pharmaco Economics; Type II Diabetes Mellitus

Indexed keywords

ACETYLSALICYLIC ACID; CAPTOPRIL; CHLORPROPAMIDE; FUROSEMIDE; GLIBENCLAMIDE; HYDROCHLOROTHIAZIDE; INSULIN; LISINOPRIL; METFORMIN; METHYLDOPA; NIFEDIPINE;

ARTICLE; COST OF ILLNESS; DIAGNOSTIC TEST; DRUG COST; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MONITORING; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT TRANSPORT;

EID: 84896486947     PISSN: None     EISSN: 09751491     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Bakari AG, Onyemelukwe GC. Glucose intolerance among apparently healthy Hausa-Fulani in North-Eastern Nigerian. Ann Afr Med 2004; 3: 32-34.
2. World Health Organization. Defined daily dose approach to economic evaluation of drug therapy. WHO Health economics and Health sector reform document WHO/HE/HSR 2007; 1-176.
3. Cantrill JA. Diabetes Mellitus In: Walker R, Edward C, editors. Text Book of Clinical Pharmacy and Therapeutics. 2nd ed. USA: Mc Graw-Hill companies Inc; 1999. P. 633-52.
4. Drummond MF. Cost of Illness Studies: a major headache. Pharmacoeconomics 1999; 2: 1-4.
5. Townsend RH. Post Marketing Drug Research and Development. Drug Intel Clin Phar 1987; 21:134-6.
6. Araoye MO. Sample Size Determination In: Araoye MO (Eds) Text Book of Research Methodology with Statistics for Health and Social Scientists. Ilorin- Nigeria: Nathadex; 2003. p. 117-20.
7. Nertheimer AL. The defined daily dose system (DDD) for drug utilization review. Hospital Pharmacy 1986; 21: 233-41.
8. Robert MJ. Work measurement In: Brown TR, Smith MC. (eds) Handbook of institutional pharmacy practice. Baltimore: Williams and Wilkins; 1986. p. 90-110.
9. Suleiman IA, Tayo F. (2001). Pharmaco-Economic Evaluation of Streptomycin Versus Ethambutol in the Treatment of Tuberculosis in Lagos University Teaching Hospital. Nig Q J Hosp Med 2001; 11 (1-4): 3-7.
10. Giwa A, Osagbemi GK, Olayinka BO, Giwa HBF. Comparative Cost Effectiveness Analysis of Streptomycin and Ethambutol in the Treatment of Tuberculosis in a University Teaching Hospital in Nigeria. Afr. J. Cln. Exper. Microbiol 2009; 10 (I): 47-55.
11. American Diabetes Association (2003). Treatment of hypertension in adult with diabetes. Diabetes Care 2003; 26 (suppl. 1): 582.
12. Federal Ministry of Health. Medicine Prices in Nigeria: Prices people pay for medicines. Publication of Federal Ministry of Health in collaboration with World Health Organization, Department for International Development and European Union 2006. p. 1-38.
13. British National Formulary (1998). Treatment of diabetes nephropathy and neuropathy. BNF 1998. Vol. 36. p. 307.
14. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JAMA). The seventh report 2003. 289: 2560-72.
15. National Population Commission. Projected Population Figure using Annual Growth Rate. NPC Report 2006. p. 1-46.
16. Gray A, Fenn P, Mc-Guire A. (1995). The cost of insulin dependent diabetes mellitus (IDDM) in England and Wales. Diabetic Med 1995; 12: 1068-76.
17. World Health Organization. Arising Global Burden of Diabetes. WHO Diabetes Programme/WHO Diabetes Action, now booklet on country and regional data on diabetes mellitus 2010. p. 1-326.
18. Federal Office of Statistics. Nigerian Poverty Profile: 1980-1999. FOS/NPP/80-99 Document 1999. p. 1-64.
19. United Nations Development Programme (UNDP). Poverty situation in Nigeria. Technical report on Nigeria (UNDP/POV/NIG/04) 2004. p. 1-27.
20. Robinson NL, Cesl K. (1998). Social deprivation and mortality in adult with diabetes mellitus. Diabetic Med 1998; 15: 205-12.
21. Nilsson PM, Johansson SE, Sundquis J. Low educational status is a risk factor for mortality among diabetic people. Diabetic Med 1998; 15: 213-19.
22. Currie CJ, Kraus D, Morgan CL, Gill L, Stott NCH, Peters JR. (1887). Acute sector expenditure for diabetes: the present, future and excess in-patient cost of care. Diabetic Med 1987; 14: 686-92.
23. Giwa A, Osagbemi GK, Atata RF, Giwa HBF. Comparative Pharmacoeconomic Analysis of Benzathine Penicillin and Procaine Penicillin in the treatment of early syphilis in a University Teaching Hospital in Nigeria. Journal of Pharmacy and Bio 2008; 5(2): 41-46.
24. Giwa A, Osagbemi GK, Atata RF, Giwa HBF. Cost-minimization Analysis of Antimicrobial Therapy in A Tertiary Healthcare institution in Nigeria. Journal of Pharmacy and Bio 2008; 5(2): 47-51.
25. Giwa A, Osagbemi GK, Olayinka BO and Giwa HBF. Pharmacoeconomic Evaluation of Doxycycline and Tetracycline in the Treatment of Chlamydia Implicated Non-Gonococcal Urethritis in a Tertiary Healthcare institution in Nigeria. Afr. J. Cln. Exper. Microbiol 2009; 10 (1): 38-46.
26. Giwa A, Tayo F (2013). Poverty, Affordability of Anti-Diabetic Drugs and Glycemic Control: An Unholy Alliance in a Developing Economy?. Int J Pharm Sci Res 2013; 4 (9): 113-120.